CuraGen Corporation (NASDAQ: CRGN), a biopharmaceutical company, is devoted to improving the lives of patients by developing pharmaceutical products that address medical needs that are currently unmet. The company’s therapeutics are based on the research of novel drug targets and mechanisms that are believed to play a role in underlying diseases. Through its efforts, CuraGen has utilized this research and understanding to develop a pipeline of protein, antibody, and antibody-drug conjugate drugs. For further information, visit the Company’s web site at www.curagen.com.
- 18 years ago
QualityStocks
CuraGen Corporation (NASDAQ: CRGN)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Expands Heidelberg R&D Facilities To Support Drug Development Pipeline
VERAXA Biotech (NASDAQ: VRXA) an emerging developer of novel cancer therapies, announced it has expanded…
-
QualityStocksNewsBreaks – Hallmark Venture Group, Inc. (OTC: HLLK) Completes Drone Technology Acquisition, Transitions to Operating Business
Hallmark Venture Group (OTC: HLLK) announced the completion of a strategic transaction that transforms the company from…
-
QualityStocksNewsBreaks – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Featured in BioMedWire Editorial on DNA Repair Cancer Therapies
This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising. Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) announced…